#Incretin mimetics
GLP-1, GIP, glucagon receptor agonists.
GLP-1/GIPR/FGF21 peptibody in DIO mice
A preclinical peptibody hitting GLP-1, GIPR, and FGF21 reduced body weight and improved metabolic markers in obese mice. Human translation is unknown.
How semaglutide works across the body
A 2026 review reads semaglutide through a systems medicine lens, tracing the GLP-1 receptor agonist from trial outcomes to the molecular mediators underneath.
Switching Peptides: What the Evidence Says
No clinical guideline covers switching between incretin-class peptides. Prescribing information and early research both say: start at the lowest dose.
Mounjaro and Zepbound: same drug, different names. Here is why
Mounjaro and Zepbound are both Eli Lilly's tirzepatide. Same molecule, same doses, different brands sold for different indications. The marketing split is regulatory, not pharmacological.
TRIUMPH-1: retatrutide hits 28.3% weight loss at 80 weeks
Eli Lilly's first general-obesity Phase 3 readout for retatrutide: 28.3% mean body-weight reduction at 80 weeks on 12 mg weekly. Larger than any SURMOUNT-5 figure to date.